Exagen director awarded 37,500 stock options

Exagen Inc. director Chas McKhann received a grant of stock options covering 37,500 shares of common stock at an exercise price of $4.31 per share.

Rhea-AI Filing Summary

Exagen Inc. director Chas McKhann received a grant of stock options covering 37,500 shares of common stock at an exercise price of $4.31 per share. These options vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued board service. Following this grant, McKhann holds options on 45,000 shares in total, which are scheduled to expire on June 8, 2036.

Insider Trade Summary

Grant/Award: 37,500 shares

Grant/Award 1 txn

Insider McKhann Chas

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option(right to buy)	37,500	$0.00	$0.00

Holdings After Transaction: Stock Option(right to buy) — 45,000 contracts (Direct)

Footnotes (1)

1. F1. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Key Figures

Options granted: 37,500 options Exercise price: $4.31 per share Total options after grant: 45,000 options +1 more

4 metrics

Options granted 37,500 options Grant to director on June 9, 2026

Exercise price $4.31 per share Strike price of granted options

Total options after grant 45,000 options Director holdings following transaction

Expiration date June 8, 2036 Options termination date

Key Terms

Stock Option, exercise price, vested and exercisable, grant date

4 terms

Stock Option financial

"Stock Option(right to buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"an exercise price of $4.31 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested and exercisable financial

"becomes fully vested and exercisable on the first to occur"

grant date financial

"the first anniversary of the grant date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Exagen (XGN) report for director Chas McKhann?

Exagen reported that director Chas McKhann received a grant of 37,500 stock options. The options allow him to buy common shares at an exercise price of $4.31 per share, according to a Form 4 insider filing.

What is the exercise price of the new Exagen (XGN) stock options?

The new stock options granted to director Chas McKhann have an exercise price of $4.31 per share. This is the price at which he can purchase Exagen common stock if he exercises the options.

When do Chas McKhann’s Exagen (XGN) stock options vest?

The options vest in full on the first anniversary of the grant date or at the next annual stockholder meeting, whichever comes first. Vesting is conditioned on his continued service on Exagen’s board through that date.

How many Exagen (XGN) options does Chas McKhann hold after this grant?

After this grant, Chas McKhann holds options covering 45,000 shares of Exagen common stock. This total includes the newly granted 37,500 options reported in the Form 4 filing.

When do Chas McKhann’s newly granted Exagen (XGN) options expire?

The newly granted stock options to Chas McKhann are scheduled to expire on June 8, 2036. If not exercised by that date, the options will terminate and no longer be usable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 01:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKhann Chas

(Last) (First) (Middle)

1261 LIBERTY WAY

(Street)

VISTA CALIFORNIA 92081

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXAGEN INC. [ XGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(right to buy)	$4.31	06/09/2026		A		37,500		06/09/2026	06/08/2036(1)	Common Stock	37,500	$0	45,000	D

Explanation of Responses:

1. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Remarks:

	/s/ Jeffrey G. Black, as attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)